Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI

Executive Summary

Stakeholders wonder about impact of placing orphan drug program staff "into review teams" as part of next iteration of user fee program.

You may also be interested in...



PDUFA VII: US FDA Will Offer Additional Meetings To Boost Rare Disease Endpoint Development

If they reach a public disclosure agreement, a handful of sponsors will be admitted to a new pilot program that allows four meetings with the FDA on rare disease endpoint issues.

US FDA's New Drug Assessors More Experienced With Rare Disease Issues

Now most, if not all, assessment divisions within the Office of New Drugs have dealt with issues surrounding small trials and rare diseases, defying common belief that experience was spread unequally.

US FDA Should Offer Formal Declaration Of Orphan Drug Flexibility, Attorney Says

Attorney Frank Sasinowski says the agency should include new "boilerplate language" in official documents describing scientific flexibility for orphan drug approval requirements.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS118795

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel